Recursion Pharmaceuticals Files 8-K

TL;DR

RXRX filed an 8-K on Nov 26, 2025, updating corporate info. Nothing major.

AI Summary

Recursion Pharmaceuticals, Inc. filed an 8-K on November 26, 2025, reporting on other events and financial statements. The filing details the company's principal executive offices located at 41 S Rio Grande Street, Salt Lake City, UT 84101, and its telephone number (385) 269-0203. The company was incorporated in Delaware and its fiscal year ends on December 31.

Why It Matters

This 8-K filing provides an update on Recursion Pharmaceuticals' corporate information and events, which is important for investors to stay informed about the company's operational status and reporting.

Risk Assessment

Risk Level: low — This filing is a routine corporate update and does not contain significant new financial information or strategic changes that would immediately impact risk.

Key Numbers

• 2025-11-26 — Filing Date (The date the 8-K was filed with the SEC.)
• 1231 — Fiscal Year End (Indicates the end of Recursion Pharmaceuticals' fiscal year.)

Key Players & Entities

• RECURSION PHARMACEUTICALS, INC. (company) — Registrant
• November 26, 2025 (date) — Date of earliest event reported
• 41 S Rio Grande Street, Salt Lake City, UT 84101 (location) — Address of principal executive offices
• 001-40323 (company) — SEC File Number
• 46-4099738 (company) — I.R.S. Employer Identification No.

FAQ

Key Financial Figures

• $0.00001 — stered Class A Common Stock, par value $0.00001 per share RXRX Nasdaq Global Select Mar

Filing Documents

• rxrx-20251126.htm (8-K) — 23KB
• exhibit51-wsgropiniontempu.htm (EX-5.1) — 11KB
• image_1.jpg (GRAPHIC) — 67KB
• 0001601830-25-000172.txt ( ) — 239KB
• rxrx-20251126.xsd (EX-101.SCH) — 2KB
• rxrx-20251126_lab.xml (EX-101.LAB) — 21KB
• rxrx-20251126_pre.xml (EX-101.PRE) — 12KB
• rxrx-20251126_htm.xml (XML) — 3KB

01. Other Events

Item 8.01. Other Events. On November 26, 2025, Recursion Pharmaceuticals, Inc. ("Recursion") filed a prospectus supplement dated November 26, 2025 (the "Tempus Prospectus Supplement") and an accompanying base prospectus, which are part of Recursion's automatic "shelf" Registration Statement on Form S-3ASR (File No. 333-284878) (the "Registration Statement"), which was previously filed on February 12, 2025 with the Securities and Exchange Commission (the "SEC"). The Tempus Prospectus Supplement was filed to register for resale 7,088,742 shares of Recursion's Class A common stock (the "Tempus Shares") that were issued to Tempus AI, Inc. (f/k/a Tempus Labs, Inc.) ("Tempus") on November 24, 2025 in payment for annual license fees paid under the terms of that certain Master Agreement entered into by and between Recursion and Tempus as further described in Recursion's Current Report on Form 8-K filed with the SEC on November 9, 2023, which is incorporated herein by reference. The offering of the Tempus Shares was made pursuant to an exemption from registration under the Securities Act of 1933, as amended. A copy of the opinion of Wilson Sonsini Goodrich & Rosati, P.C. relating to the legality of the Tempus Shares is filed herewith as Exhibit 5.1.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 5.1 Opinion of Wilson Sonsini Goodrich & Rosati, P.C. 23.1 Consent of Wilson Sonsini Goodrich & Rosati, P.C. (included in Exhibit 5.1 ). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on November 26, 2025. RECURSION PHARMACEUTICALS, INC. By: /s/ Nathan Hatfield Nathan Hatfield Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR